Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

BPI-9016M

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Betta Pharma

Drug class:

c-MET inhibitor, AXL inhibitor

Related drugs:

‹

PF-07265807 (0)

savolitinib (29)

amivantamab-vmjw (25)

capmatinib (23)

unecritinib (6)

gumarontinib (5)

JNJ-38877605 (1)

EMD 1204831 (0)

PF-04217903 (0)

PF-07265807 (0)

›

MET exon 14 mutation	Non Small Cell Lung Cancer	MET exon 14 mutation	Non Small Cell Lung Cancer	BPI-9016M Sensitive: C2 – Inclusion Criteria BPI-9016M Sensitive : C2	BPI-9016M Sensitive: C2 – Inclusion Criteria BPI-9016M Sensitive : C2
MET overexpression	Non Small Cell Lung Cancer	MET overexpression	Non Small Cell Lung Cancer	BPI-9016M Sensitive: C3 – Early Trials BPI-9016M Sensitive : C3	BPI-9016M Sensitive: C3 – Early Trials BPI-9016M Sensitive : C3